Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169179 | 0.81 | HTR1A (0.47) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL27541275 | 0.80 | CCNT1 (0.59) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL30579418 | 0.77 | CCNT1 (0.67) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL6166811 | 0.76 | KMT2A (0.52) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL6169123 | 0.76 | KMT2A (0.52) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL6168420 | 0.76 | HTR2A (0.49) | HTR1AKMT2APOLBSLC2A1RAD52 | |
| SCHEMBL4900043 | 0.74 | EIF2AK2 (0.75) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL4907259 | 0.72 | CCNT1 (0.66) | EIF2AK2CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL734448 | 0.71 | HTR2A (0.56) | HTR1AADORA2AKMT2APOLBHTR2A | |
| SCHEMBL4017867 | 0.71 | MC5R (0.71) | HTR1AKMT2APOLBHTR2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | FREDERICKSON MARTYN (GB) | 2005-06-09 | — | — | US | claimed |
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | FREDERICKSON MARTYN (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1495016-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | Astex Technology Limited (GB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | MAPK1, IDO1, INMT | EIF2AK2 256/4885CCNT1 161/4885CCNA2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.